Neovascular age-related macular degeneration Trials in Beverly Hills, United States
Conditions / Neovascular age-related macular degeneration / Beverly Hills, United States
Neovascular age-related macular degeneration is a medical condition with active clinical research programs worldwide.
28 total trials for this combination
Showing top 10 of 28 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02713204 | Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection | COMPLETED | PHASE2 |
| NCT03345082 | A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD | COMPLETED | PHASE2 |
| NCT03577899 | Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) | TERMINATED | PHASE3 |
| NCT03834753 | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |
| NCT02418754 | Study of Intravitreal REGN2176-3 in Participants With Neovascular (Wet) Age-Related Macular Degeneration (AMD) | TERMINATED | PHASE2 |
| NCT03677934 | A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration | COMPLETED | PHASE3 |
| NCT06491914 | A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03683251 | Extension Study for the Port Delivery System With Ranibizumab (Portal) | RECRUITING | — |
| NCT04704921 | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | ACTIVE_NOT_RECRUITING | — |
| NCT00964795 | Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (Wet) Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |